Developmental Funds continue to represent an important and critical institutional resource to support newly recruited faculty without prior peer-reviewed support into the 19 Basic Science, Clinical and Populationbased Research Programs of MDACC, to develop new shared resources in response to the research needs of peer-reviewed investigators, and to support multidisciplinary research programs. A significant increase in Developmental Funds is requested in this competitive renewal based on the institution's careful stewardship and successful return on the funds invested in newly recruited faculty during the current grant period, the plans for the Monoclonal Antibody Facility, Molecular Cytogenetics Facility, Immune Monitoring Core Laboratory, and the pilot projects of the Multidisciplinary Research Programs. Processes are in place within the institution to solicit proposals for support from CCSG Developmental Funds and to review them for scientific merit and programmatic relevance. The Developmental Funds requested will be leveraged with institutional resources to insure the scientific growth and excellence of MDACC's research programs, including the continued recruitment of outstanding new junior faculty, the ability to provide the necessary shared resource infrastructure to support research initiatives, and the flexibility to capitalize on new and innovative research leads. The Developmental Funds will provide the Director of the Cancer Center with a stable source of support for a variety of activities critical to maintaining the research strength and interactive environment characteristic of the MDACC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-36
Application #
8310867
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
36
Fiscal Year
2011
Total Cost
$965,415
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Wilson Dib, Rita; Chaftari, Anne-Marie; Hachem, Ray Y et al. (2018) Catheter-Related Staphylococcus aureus Bacteremia and Septic Thrombosis: The Role of Anticoagulation Therapy and Duration of Intravenous Antibiotic Therapy. Open Forum Infect Dis 5:ofy249
Ji, Shuang; Ning, Jing; Qin, Jing et al. (2018) Conditional independence test by generalized Kendall's tau with generalized odds ratio. Stat Methods Med Res 27:3224-3235
McNeill, Lorna H; Reitzel, Lorraine R; Escoto, Kamisha H et al. (2018) Engaging Black Churches to Address Cancer Health Disparities: Project CHURCH. Front Public Health 6:191
Hosry, Jeff; Miranda, Roberto N; Samaniego, Felipe et al. (2018) Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in hepatitis C virus-infected patients. Int J Cancer 142:940-948
Parkes, Amanda; Clifton, Katherine; Al-Awadhi, Aydah et al. (2018) Characterization of bone only metastasis patients with respect to tumor subtypes. NPJ Breast Cancer 4:2
Raber, Margaret; Huynh, To Nhu; Crawford, Karla et al. (2018) Development and Feasibility of a Community-Based, Culturally Flexible Colorectal Cancer Prevention Program. J Community Health 43:882-885
Wang, Xiaoxiao; Cao, Xin; Sun, Ruifang et al. (2018) Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. Neoplasia 20:574-593
Koay, Eugene J; Owen, Dawn; Das, Prajnan (2018) Radiation-Induced Liver Disease and Modern Radiotherapy. Semin Radiat Oncol 28:321-331
Zhang, Yan; Coletta, Adriana M; Allen, Pamela K et al. (2018) Perirenal Adiposity is Associated With Lower Progression-Free Survival From Ovarian Cancer. Int J Gynecol Cancer 28:285-292
Rausch, Caitlin R; DiPippo, Adam J; Bose, Prithviraj et al. (2018) Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole. Clin Infect Dis 67:1610-1613

Showing the most recent 10 out of 12418 publications